Discrepant clinicopathologic characteristics and HE4 performance in type I and type II epithelial ovarian cancer.

about

Diagnostic value of HE4+ circulating tumor cells in patients with suspicious ovarian cancer.

P2860

Q50328403-257AE9A0-CBBB-4F6A-9278-DB4BBBFBBAEB

P2860

Discrepant clinicopathologic characteristics and HE4 performance in type I and type II epithelial ovarian cancer.

Item

http://www.wikidata.org/entity/Q35925743

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Discrepant clinicopathologic c ...... II epithelial ovarian cancer.

@ast

Discrepant clinicopathologic c ...... II epithelial ovarian cancer.

@en

type

Item

label

Discrepant clinicopathologic c ...... II epithelial ovarian cancer.

@ast

Discrepant clinicopathologic c ...... II epithelial ovarian cancer.

@en

prefLabel

Discrepant clinicopathologic c ...... II epithelial ovarian cancer.

@ast

Discrepant clinicopathologic c ...... II epithelial ovarian cancer.

@en

P1476

Discrepant clinicopathologic c ...... II epithelial ovarian cancer.

@en

P2093

Di Bo

http://www.w3.org/2001/XMLSchema#string

Heng Cui

http://www.w3.org/2001/XMLSchema#string

Hongyan Cheng

http://www.w3.org/2001/XMLSchema#string

Jinghong Jiang

http://www.w3.org/2001/XMLSchema#string

Xiaohong Chang

http://www.w3.org/2001/XMLSchema#string

Xue Ye

http://www.w3.org/2001/XMLSchema#string

P2860

Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory

The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma.

Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas.

Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm.

Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass.

Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer.

Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response.

Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention.

P304

21303-21310

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-11-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26885070

http://www.w3.org/2001/XMLSchema#string

P921

ovarian cancer

P932

4723915

http://www.w3.org/2001/XMLSchema#string

Discrepant clinicopathologic characteristics and HE4 performance in type I and type II epithelial ovarian cancer.

about

P2860

P2860

Discrepant clinicopathologic characteristics and HE4 performance in type I and type II epithelial ovarian cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P433

P478

P577

P698

P921

P932

P1433

P1476

P2093

P2860

P304

P31

P433

P478

P577

P698

P921

P932